Dermatology co Foamix mulls Nasdaq IPO
Teva's share price plunged after Biogen reported data from its oral multiple sclerosis drug, BG-12, a rival to Teva's Laquinimod.
The share price of Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) tumbled 10% to $44.25 in premarket trading on the Nasdaq today after rival Biogen Idec Inc (Nasdaq: BIIB) reported positive data from its Phase III clinical trial of its oral multiple sclerosis drug, BG-12, and shares jumped 21 percent in premarket trading on Thursday. BG-12 is a rival to Teva's Laqunimod.
Biogen Idec's soared 26.5% in premarket trading to $109.50, giving cap of $20 billion.
The last time that Teva's share traded at $45 was in May 2009, during the rally that began in March 2009 following the global financial crisis.
In the conference call following the financial report for the first quarter, Biogen executives said that BG-12 cut the proportion of patients who relapsed by 49% and reduced the rate of progression by 38T percent after two years compared with placebo.
Clal Finance analyst Jonathan Kreizman told "Globes", "For a long time, Teva has been building market expectations that Laquinimod will be a dominant drug in its field. Today's information shows that it has a worthy rival in addition to Gilenya, developed by Novartis AG (NYSE:NVS; LSE: NOV; SWX: NOVZ).
Biogen sells two drugs that compete against Teva's Copaxone: Avonex and Tysabri (jointly owned by Ireland's Elan Corporation plc’s (NYSE: ELN; ISE: DRX). Biogen's BG-12 will complete against Laquinimod, which is due to reach market in 2012.
Copaxone had over $3 billion in sales in 2010, accounting for a third of Teva's profits. The map of multiple sclerosis treatments is changing as oral drugs come on the market and Copaxone will likely lose its high standing.
At the 63rd American Academy of Neurology (AAN) conference in Honolulu earlier this month, Biogen presented positive data about BG-12, as did Teva about Laquinimod. Today, Biogen CEO Dr. George Scangos was optimistic about BG-12, mentioning the positive results in the clinical trial.
It seems that investors considered Scangos' optimism as reason to be worried about Teva. Bernstein Research analyst Roni Gal said that the good results of BG-12 puts it in a good position against Laquinimod and other oral multiple sclerosis drugs. He said that BG-12 results were close to those achieved by Novartis's Gilenya, which is already on the market. However, he is cautious about the lack of safety profiles for the drug, and he believes Laquinimod will find its place in the market.
According to Biogen's financial report, Avonex had $642.5 million in sales in the first quarter and Tysabri had $251.4 million.
Teva will publish its financial report for the first quarter on May 11.
Teva's share price fell 1.7% on the TASE today to NIS 165.50, before Biogen Idec's announcement.
Published by Globes [online], Israel business news - www.globes-online.com - on April 21, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011
You comment was recieved and soon will be published.
Load more comments
The developer of foam-based dermatology treatments is seeking underwriters.
Can-Fite Biopharma raises $5m
The proceeds will finance clinical trials for psoriasis, glaucoma, and liver cancer treatments.
Teva switching Copaxone users to new dosage
"Bloomberg": Teva has switched 8.7% of Copaxone's multiple sclerosis patients to the 40 milligram dosage.
Immune Pharmaceuticals raises $11.7m on Nasdaq
The money raised will fund a Phase II trial of ulcerative colitis drug bertilmumab.
XTL Biopharma files to raise $40m on Nasdaq
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.